Valuation: EnteroMedics Inc

Market Cap 1.43Cr 1.26Cr 1.19Cr 1.08Cr 2.02Cr 137.23Cr 2.04Cr 14Cr 5.5Cr 70Cr 5.38Cr 5.26Cr 225.32Cr P/E 2026 *
-3.74x
P/E 2027 * -2.55x
Enterprise Value 1.43Cr 1.26Cr 1.19Cr 1.08Cr 2.02Cr 137.23Cr 2.04Cr 14Cr 5.5Cr 70Cr 5.38Cr 5.26Cr 225.32Cr EV / Sales 2026 *
131x
EV / Sales 2027 * 71.6x
Free-Float
-
Yield 2026 *
-
Yield 2027 * -

Financials

2026 *2027 *
Net sales 1L 96.09T 90.75T 82.7T 2L 1.05Cr 2L 10.86L 4L 53.62L 4L 4L 1.72Cr 2L 2L 2L 2L 3L 1.92Cr 3L 19.83L 8L 97.93L 8L 7L 3.15Cr
Net income -38L -33.34L -31.49L -28.7L -53.72L -36Cr -54.11L -3.77Cr -1.46Cr -19Cr -1.43Cr -1.4Cr -60Cr -78.46L -68.85L -65.02L -59.26L -1.11Cr -75Cr -1.12Cr -7.78Cr -3.01Cr -38Cr -2.95Cr -2.88Cr -123.47Cr
Net Debt - -
Logo EnteroMedics Inc
ReShape Lifesciences Inc. is a weight-loss and metabolic health-solutions company. The Company offers an integrated portfolio of products and services that manage and treat obesity and metabolic disease. Its Lap-Band System provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures, such as gastric bypass or sleeve gastrectomy. The investigational Diabetes Bloc-Stim Neuromodulation (DBSN) system utilizes a vagus nerve block and stimulation technology platform for the treatment of type II diabetes and metabolic disorders. The Obalon balloon technology is a non-surgical, swallowable, gas-filled intra-gastric balloon that is designed to provide long-lasting weight loss. Its ReShape Calibration tubes are multifunctional devices compared to reusable bougies and disposable gastric tubes. Its Lap-Band 2.0, like the original Lap-Band System, is designed to provide minimally invasive long-term treatment of severe obesity.
Employees
-
Sector
-